Biomarkers may assist clinicians in the diagnosis, assessment of disease severity, and monitoring of treatment response in patients with pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Biomarkers warrant exploratory use in pulmonary hypertension; leaves open prospective validation before clinical adoption.
Warwick et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: